Roche to Halt Lung Cancer Drug Study in Fresh Setback [BNN Bloomberg (Canada)]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: BNN Bloomberg
The medicine, called tiragolumab, was combined with another Roche treatment and chemotherapy in the clinical trial. The trio appeared less effective than Merck & Co.'s best-seller Keytruda and chemotherapy in the test, the Swiss drugmaker said in a statement. The trial failure is the latest in a series of drug-development setbacks for Roche, following disappointments in Alzheimer's disease and in cancer. Chief Executive Officer Thomas Schinecker pledged last year to make the company quicker and more efficient at developing new medicines. The shares dropped as much as 3.2% in early trading in Zurich. Roche has fallen 1.7% so far this year. The experimental treatment that stumbled on Thursday has a checkered history: It failed in a different crucial lung cancer study two years ago, yet last year some accidentally disclosed data hinted that the study might be successful after all. Roche said it will assess whether changes need to be made to other studies of the experimental drug
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Stock Market News for Oct 4, 2024 [Yahoo! Finance]Yahoo! Finance
- Should Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? [Yahoo! Finance]Yahoo! Finance
- Could Summit Therapeutics Become the Next Merck? [Yahoo! Finance]Yahoo! Finance
- U.S. In Vitro Fertilization Market Analysis Report 2024-2030: Societal Norms and Attitudes Shift, Driving IVF Demand [Yahoo! Finance]Yahoo! Finance
- ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 7/30/24 - Beat
MRK
Sec Filings
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- 10/1/24 - Form 4
- MRK's page on the SEC website